Promising Therapeutics against Ebola Virus Disease

References (69)

1. 1 Interaction of silver nanoparticles with HIV-1 [DOI]
2. 2 Ebola haemorrhagic fever [DOI]
3. 3 Antisense technologies [DOI]
4. 4 Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp [DOI]
5. 5 Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430 [DOI]
6. 6 New Antimicrobials of Plant Origin
7. 7 Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model [DOI]
8. 8 Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study [DOI]
9. 9 Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys [DOI]
10. 10 Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques [DOI]
11. 11 A case of Ebola virus infection. [DOI]
12. 12 Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies [DOI]
13. 13 Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance [DOI]
14. 14 Evaluation of Immune Globulin and Recombinant Interferon‐α2b for Treatment of Experimental Ebola Virus Infections [DOI]
15. 15 Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease [DOI]
16. 16 Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge Is Conferred by RNA Interference [DOI]
17. 17 Interaction of silver nanoparticles with Tacaribe virus [DOI]
18. 18 Neutralizing Antibody Fails to Impact the Course of Ebola Virus Infection in Monkeys [DOI]
19. 19 The 2014 Ebola virus disease outbreak in West Africa [DOI]
20. 20 Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monoclonal Antibody Cocktail [DOI]
21. 21 Advanced antisense therapies for postexposure protection against lethal filovirus infections [DOI]
22. 22 Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses [DOI]
23. 23 Recombinant Human Activated Protein C for the Postexposure Treatment of Ebola Hemorrhagic Fever [DOI]
24. 24 Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers [DOI]
25. 25 Favipiravir elicits antiviral mutagenesis during virus replication in vivo [DOI]
26. 26 Ebola Virus Pathogenesis: Implications for Vaccines and Therapies [DOI]
27. 27 Multiple Cationic Amphiphiles Induce a Niemann-Pick C Phenotype and Inhibit Ebola Virus Entry and Infection [DOI]
28. 28 Ebola virus disease: a review on epidemiology, symptoms, treatment and pathogenesis [DOI]
29. 29 mAbs and Ad-Vectored IFN-α Therapy Rescue Ebola-Infected Nonhuman Primates When Administered After the Detection of Viremia and Symptoms [DOI]
30. 30 Preparation and Use of Hyperimmune Serum for Prophylaxis and Therapy of Ebola Virus Infections [DOI]
31. 31 Ebola Hemorrhagic Fever: Evaluation of Passive Immunotherapy in Nonhuman Primates [DOI]
32. 32 Interferon-β Therapy Prolongs Survival in Rhesus Macaque Models of Ebola and Marburg Hemorrhagic Fever [DOI]
33. 33 Broad Spectrum Antiviral Activity of Favipiravir (T-705): Protection from Highly Lethal Inhalational Rift Valley Fever [DOI]
34. 34 Dose regimen of favipiravir for Ebola virus disease [DOI]
35. 35 Ebola GP-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection [DOI]
36. 36 Passive Transfer of Antibodies Protects Immunocompetent and Immunodeficient Mice against Lethal Ebola Virus Infection without Complete Inhibition of Viral Replication [DOI]
37. 37 Antiviral Drug Therapy of Filovirus Infections: S‐Adenosylhomocysteine Hydrolase Inhibitors Inhibit Ebola Virus In Vitro and in a Lethal Mouse Model [DOI]
38. 38 Recombinant Human Monoclonal Antibodies to Ebola Virus [DOI]
39. 39 EbolavirusVP35 is a multifunctional virulence factor [DOI]
40. 40 Protection Against Lethal Marburg Virus Infection Mediated by Lipid Encapsulated Small Interfering RNA [DOI]
41. 41 Profile and Persistence of the Virus-Specific Neutralizing Humoral Immune Response in Human Survivors of Sudan Ebolavirus (Gulu) [DOI]
42. 42 Ebola drug trials set to begin amid crisis [DOI]
43. 43 One Step Closer to an Ebola Virus Vaccine [DOI]
44. 44 Ebola therapy protects severely ill monkeys [DOI]
45. 45 Oral melatonin reduces blood coagulation activity: a placebo‐controlled study in healthy young men [DOI]
46. 46 Melatonin reduces oxidative damage to skin and normalizes blood coagulation in a rat model of thermal injury [DOI]
47. 47 Effect of oral melatonin on the procoagulant response to acute psychosocial stress in healthy men: a randomized placebo‐controlled study [DOI]
48. 48 Potential clinical treatment for Ebola pandemic [DOI]
49. 49 Ebola Outbreak in Africa: Current Issues - A Mini Review [DOI]
50. 50 Hyperimmune serum from healthy vaccinated individuals for Ebola virus disease? [DOI]
51. 51 Ebola Virus Disease in West Africa — The First 9 Months of the Epidemic and Forward Projections [DOI]
52. 52 Ebola Virus VP24 Binds Karyopherin α1 and Blocks STAT1 Nuclear Accumulation [DOI]
53. 53 FDA-Approved Selective Estrogen Receptor Modulators Inhibit Ebola Virus Infection [DOI]
54. 54 Pre- and Postexposure Prophylaxis of Ebola Virus Infection in an Animal Model by Passive Transfer of a Neutralizing Human Antibody [DOI]
55. 55 Protective Efficacy of Neutralizing Monoclonal Antibodies in a Nonhuman Primate Model of Ebola Hemorrhagic Fever [DOI]
56. 56 Emerging Viral Diseases: Confronting Threats with New Technologies [DOI]
57. 57 Potential and Emerging Treatment Options for Ebola Virus Disease [DOI]
58. 58 Ebola virus disease: potential use of melatonin as a treatment [DOI]
59. 59 First Ebola treatment is approved by WHO [DOI]
60. 60 Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization [DOI]
61. 61 VP35 Knockdown Inhibits Ebola Virus Amplification and Protects against Lethal Infection in Mice [DOI]
62. 62 RNAi Therapeutics and Applications of MicroRNAs in Cancer Treatment [DOI]
63. 63 Impact of Ebola Mucin-Like Domain on Antiglycoprotein Antibody Responses Induced by Ebola Virus-Like Particles [DOI]
64. 64 A Practical Treatment for Patients With Ebola Virus Disease [DOI]
65. 65 Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus [DOI]
66. 66 Estimation of toxic effects of chemically and biologically synthesized silver nanoparticles on human gut microflora containing Bacillus subtilis [DOI]
67. 67 Retinazone Inhibits Certain Blood-Borne Human Viruses Including Ebola Virus Zaire [DOI]
68. 68 The 2014 Ebola Virus Outbreak in West Africa: Current Perspectives for Prevention and Treatment [DOI]
69. 69 How the Spread of Ebola Virus was Curtailed in Nigeria [DOI]

Cited by 2

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

• Molecules of Interest – Mangiferin – A Review — shares topic coverage
• Low-dose Sekikaic Acid Modulates Host Immunity and Protects Cells from Respiratory Syncytial Virus Infection — shares topic coverage
• Preliminary Phytochemical Screening and Antiviral Potential of Methanol Stem Bark Extract of Enantia chlorantha Oliver (Annonaceae) and Boswellia dalzielii Hutch (Burseraceae) against Newcastle Disease In Ovo — shares topic coverage
• Phytotherapeutic Potential of Azadirachta indica: Modulating SARS-CoV-2 Viral Entry and the Endothelial Pro-inflammatory Cascade — shares topic coverage
• Antiviral Effect of Phyllanthus amarus Leaf Extract against Newcastle Disease Virus in Broilers — shares topic coverage